Eiger BioPharmaceuticals, Inc.

No trades
See on Supercharts
Market capitalization
‪8.29 M‬USD
−58.82USD
‪−96.78 M‬USD
‪13.48 M‬USD
‪1.31 M‬
Beta (1Y)
3.45

About Eiger BioPharmaceuticals, Inc.

CEO
David Apelian
Headquarters
Palo Alto
Employees (FY)
56
Founded
2008
ISIN
US28249U2042
FIGI
BBG0026ZCTG7
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Forex, Futures, Bonds
4.4Very Good

See all brokers